We advised the underwriters on the offering

Davis Polk advised the underwriters in connection with an SEC-registered direct offering by Alector, Inc. of 36,600,000 shares of common stock at $2.05 per share for total gross proceeds of approximately $75 million. Alector’s common stock is listed on the Nasdaq Global Select Market under the symbol “ALEC.”

Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins and restore immune and nerve cell function.

The Davis Polk corporate team included partners Alan F. Denenberg and Marcel Fausten and associates Dove Barbanel, Jared Madnick, Ashley Jaworoski and Joon Ko. Partner David R. Bauer provided intellectual property advice. Counsel Dustin Plotnick and associate Hunter P. Shaw provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post